Arabinoxylan

Arabinoxylan

Arabinoxylan (AX) is a hemicellulosic, non-digestible dietary fiber polysaccharide found ubiquitously in the cell walls of cereal grains. It has attracted sustained scientific interest as a prebiotic, a modulator of blood glucose, a cardiovascular-risk-reducing agent, and — in its modified, enzymatically treated form — as an immunomodulatory nutraceutical. The following article reviews its identity, natural occurrence, historical context, chemistry, mechanisms of action, clinical evidence by health domain, dosage data from human studies, and safety profile.

1. Identity, Chemical Names, and Classification

Arabinoxylans are the main hemicellulosic polysaccharides in the cell walls of commelinid monocot plants. Arabinoxylan is a hemicellulose found in the cell walls of plants including woods, cereal grains, husk, and others. It is comprised of two pentose sugars, arabinose and xylose.

More precisely, the general structure of an AX consists of a linear β-(1→4) linked xylan backbone to which α-L-arabinofuranose units are attached as side residues via α-(1→3) and/or α-(1→2) linkages. The (1→4)-linked β-D-xylopyranosyl backbone is substituted with side-chains including O-3 and/or O-2-linked α-L-arabinofuranose units, which may be acylated on the O-5 position with ferulic acid to form feruloylated side-chains. Additional side-chain substituents include glucuronic acid and acetyl groups.

Feruloylated arabinoxylan, in which ferulic acid is linked to the arabinoxylan chain by an ester bond, has 85% soluble dietary fiber. Arabinoxylan has the unique ability to form covalent gels by the oxidative coupling of ferulic acid.

AX is a non-digestible carbohydrate composed of (1→4)-β-D-xylan polymers that contain arabinose and varying uronic acid residues. AX was formally identified as a dietary fiber by the U.S. FDA for its effect on maintenance of healthy blood glucose levels. More specifically, the FDA has identified arabinoxylan as among the isolated or synthetic non-digestible carbohydrates meeting the regulatory definition of dietary fiber.

The arabinose-to-xylose (A/X) ratio is a key structural parameter. Arabinoxylan is a complex fibre that provides a wide range of health benefits strongly regulated by its chemical structure. A strong correlation between arabinoxylan's structural properties — degree of branching, solubility, and molecular mass — and its functionalities in food systems can be observed.

Arabinoxylan is commonly abbreviated AX in the scientific literature. Its oligosaccharide breakdown products, produced during enzymatic hydrolysis, are called arabinoxylan oligosaccharides (AXOS). A commercially important enzymatically modified form derived specifically from rice bran is known as rice bran arabinoxylan compound (RBAC), sold under trade names including Biobran and MGN-3. Most research on RBAC is based on Biobran MGN-3, which consists of complex heteropolysaccharides with arabinoxylan as its primary structure while also containing galactan and glucan.

2. Natural Sources and Botanical Origin

Arabinoxylans have been identified in all major cereal grains, including wheat, barley, oats, rye, rice, sorghum, maize, and millet. In cereal grains, arabinoxylans are localized mainly in the cell walls of starchy endosperm and the aleurone layer, in the bran tissues, and in the husk of some cereals.

In the case of wheat bran, 60–69% of the non-starchy polysaccharides are arabinoxylan. Among wheat, rye, oats, rice, barley, and sorghum, rye possesses the highest amount of arabinoxylan (55% of the total dietary fiber fraction).

The psyllium husk — the papery layer around the psyllium seed — is also a major source of arabinoxylan. Psyllium husk contains total dietary fiber and arabinoxylan contents of 76.63 ± 1.32 and 46.71 ± 2.14%, respectively. Arabinoxylan constitutes 45–60% of the weight of psyllium husk.

Arabinoxylan, also known as corn heteroxylan, is the main hemicellulose found in corn and accounts for approximately 90–95% of the total corn hemicelluloses. In corn, as in other cereal grains, arabinoxylans are found in two different fractions: in the cell wall material from the endosperm and in the bran. Arabinoxylans from these two fractions show variations in chemical structures.

3. Common Forms, Preparations, and Supplement Formulations

Arabinoxylan reaches consumers in several forms:

• Intrinsic AX — present naturally in whole-grain foods such as whole-wheat bread, wholegrain rye products, oatmeal, and barley-containing foods.
• Isolated / extracted AX — purified from wheat bran, corn bran, or other cereal by-products using aqueous, alkaline, or enzymatic extraction methods. Extraction approaches include a water treatment approach and acidic or basic chemical solutions, as well as mechanical treatments (milling, extrusion, steam-pressure, ultrasound, microwave) and enzymatic treatments.
• AXOS (arabinoxylan oligosaccharides) — shorter-chain fragments generated by enzymatic hydrolysis of native AX; used as a prebiotic ingredient in functional foods and supplements.
• RBAC / Biobran / MGN-3 — rice bran arabinoxylan compound (RBAC) is derived from defatted rice bran enzymatically treated with Lentinus edodes mycelium.

Due to the physicochemical and technological properties of these molecules — e.g., water-binding capacity and gelation — arabinoxylans can also be used as a baking additive to improve dough consistency, increase loaf volumes, and improve crumb structure.

Supplement products are available as powders and capsules. The most common supplement form is Modified Arabinoxylan Rice Bran (MARB), which has been processed to enhance its bioavailability.

4. Traditional and Historical Use

Arabinoxylan as an isolated compound is a modern scientific designation; however, the cereal grains and plant husks from which it is derived have multi-millennial histories of use in food and traditional medicine across cultures.

Arabinoxylan, a hemicellulosic polysaccharide found abundantly in the cell walls of cereal grains such as wheat, rye, and barley, has a rich history of use in traditional medicine and nutrition. Historically, whole grains and their bran — rich sources of arabinoxylan — were integral to remedies for digestive health in ancient civilizations. Traditional healers in Asia and the Middle East leveraged these grains to create poultices and decoctions intended to soothe gastrointestinal discomfort, promote regularity, and support overall vitality.

Psyllium husk (Plantago ovata), one of the most concentrated natural sources of arabinoxylan, has been used in Ayurvedic medicine and traditional South Asian practice for centuries as a bulk-forming laxative and digestive tonic. Its mucilaginous character derives substantially from its high AX content.

The mucilaginous properties of arabinoxylan contributed to its reputation for calming irritated digestive tracts and aiding in natural detoxification processes. In herbal medicine, arabinoxylan-containing grains were often combined with other botanicals such as psyllium, fenugreek, and licorice root.

Rye and barley-heavy diets prevalent in Northern and Eastern European traditional cuisines implicitly provided high arabinoxylan intake, and fermented grain preparations — such as sourdough rye breads and malt-based beverages — have long been used as folk remedies for sluggish digestion. The systematic understanding of arabinoxylan as the specific active constituent, however, is a product of late 20th- and 21st-century food science.

5. Key Constituents and Mechanisms of Action

5.1 The Arabinoxylan Polymer

Arabinoxylans are very long molecules consisting of a copolymer of two pentose sugars: arabinose and xylose. The polymer is non-digestible by human gastrointestinal enzymes, meaning it transits to the large intestine largely intact, where it serves as a substrate for colonic microbial fermentation.

5.2 Ferulic Acid

The antioxidant capacity of AX is widely related to its phenolic acid content, particularly ferulic acid (FA), which is the most abundant in feruloylated AX and has been tested both in vitro and in vivo. During gut microbial fermentation, ferulic acid is released from the arabinoxylan backbone. Ferulic acid can improve antioxidase activity and decrease reactive oxygen species (ROS) concentration by activating the signaling pathway of Kelch-like ECH-associated protein-1 and nuclear factor E2-related factor-2 (Keap1-Nrf2).

The antioxidant capacity of AXs seems to be influenced by the state — bonded or free — in which ferulic acid is present within the AXs, with higher antioxidant capacity observed when bonded. Molecular weight and the degree of substitution of the AXs also influence the antioxidant capacity. AXs with lower molecular weight and degree of substitution seem to have improved antioxidant capacity.

5.3 Short-Chain Fatty Acid (SCFA) Production

Forms of feruloylated arabinoxylans are common in cereals and cereal by-products and are partially or completely fermented by gut microbiota to produce short chain fatty acids (SCFA) with the release of free ferulic acid from arabinose residues. Short chain fatty acids produced by microbial fermentation of cereal-derived arabinoxylans mainly include lactic acid, acetic acid, propionic acid, and butyric acid, which play an important role in regulating energy metabolism, immunological function, and gut cell proliferation of the host.

The fermentation of AX increases the production of acetic, propionic, and butyric acids. AX are characterized particularly by increasing butyric acid levels, which play an important role in the maintenance of health and gastrointestinal function. The fermentation of AX is associated with the growth of butyric acid-producing bacteria, such as Eubacterium and Roseburia.

5.4 SCFA Signaling

Mechanisms of dietary fiber administration on improved host health are mediated by short chain fatty acids (SCFA), which are reported to activate G protein-coupled receptors (GPR) and suppress activity of histone deacetylase (HDAC) to down-regulate expression of nuclear factor-κ-gene binding (NF-κB) signaling. Arabinoxylan is fermented by gut microbiota to produce SCFA and improve microbial community composition, intestinal barrier functions, and host health.

5.5 Glycemic Mechanisms

Although the primary function of insoluble dietary fiber is to increase fecal bulk and decrease intestinal transit time, it may also help regulate glycemic response by reducing starch-digesting enzyme activity, thereby slowing starch digestion and enhancing glycemic control. Additionally, the fermentable dietary fiber can be utilized by gut microbiota, leading to the production of short-chain fatty acids (SCFAs), which play a crucial role in glucose homeostasis.

5.6 Immunomodulatory Mechanisms (RBAC)

RBAC was found to invoke immunological activities through direct absorption via the digestive tract and interaction with immune cells at the Peyer's patches. RBAC was shown to promote innate defence by upregulating macrophage phagocytosis and enhancing natural killer cell activity while lowering oxidative stress.

Through induction of dendritic cell maturation, RBAC also augments adaptive immunity by promoting T and B lymphocyte proliferation. RBAC acts as an immunomodulator by inhibiting mast cell degranulation during allergic reactions, attenuating inflammation, and downregulating angiogenesis by modulating cytokines and growth factors.

Since lipopolysaccharide (LPS) binds to Toll-like receptor (TLR)-4 on the surface of phagocytes, low molecular weight arabinoxylan may regulate phagocytes through the same receptor.

6. Scientific Evidence by Health Domain

6.1 Gut Microbiota and Prebiotic Activity

Evidence strength: Moderate for microbiota modulation; consistent across in vitro, animal, and human studies.

Human in vivo studies have demonstrated that consumption of various species of AXs has profound effects on gut microorganisms. AX exists in different structures across cereal types.

A double-blind, placebo-controlled human intervention trial examined AXOS enriched bread. A double-blind, placebo-controlled human intervention study was undertaken with 40 healthy adult volunteers to assess the impact of consumption of breads with in situ produced AXOS (containing 2.2 g AXOS) compared to non-endoxylanase treated breads.

An in vitro fecal fermentation study confirmed the selective fermentation pattern. Results showed that rice bran arabinoxylan modified the microbiota in fecal samples from both normal-weight and overweight/obese participants compared to control, significantly increasing Collinsella, Blautia, and Bifidobacterium, and decreasing Sutterella, Bilophila, and Parabacteroides. Rice bran AX also significantly increased total and individual SCFA contents (p < 0.05). This study suggests that rice bran AX may beneficially impact gut health in obesity through prebiotic activities.

A 2021 systematic review and narrative synthesis concluded that the supplementation of intrinsic and isolated arabinoxylans leads to different alterations in gut microbiota. A subsequent 2024 systematic review and meta-analysis found that longer-chain arabinoxylans with high dose (≥10 g/day) enhanced the production of fecal propionate (SMD: 0.62; 95% CI: 0.04, 1.21), whereas shorter-chain arabinoxylan oligosaccharides (≥10 g/day) reduced isobutyrate and isovalerate. Intrinsic arabinoxylans showed greater efficacy in increasing acetate (SMD: 0.51; 95% CI: 0.19, 0.82) and butyrate levels (SMD: 0.34; 95% CI: 0.03, 0.66). The regulatory effects of arabinoxylans on the gut microbiota, and especially short-chain fatty acid production, depended on their discrete structures, intrinsic properties, and dosages.

An early 2007 study found that consumption of 2.4 g AXOS per day for 3 weeks significantly increased bifidobacteria and short chain fatty acid concentrations in healthy individuals.

A human pilot study examining the RBAC product Biobran (1 g then 3 g daily) in 10 healthy adults found that alpha and beta microbiome diversity were not associated with the experimental phase, interventional period, RBAC dosage, or time. However, the participant themselves was a statistically significant factor in alpha (p < 0.002) and beta diversity (weighted unifrac, p = 0.001). Explanatory factors including diet and lifestyle were significantly associated with alpha (p < 0.05) and beta (p < 0.01) diversity. This small trial highlights the importance of individual variability and baseline diet in determining gut microbiota responses.

Numerous studies have reported the effects of AX(OS)s on different taxa and metabolites, yet there is a lack of systematic review and meta-analysis of evidence based on clinical interventions assessing the effects of different types and sources of arabinoxylans on the composition and function of the gut microbiota.

6.2 Inflammatory Bowel Disease (IBD) and Colitis

Evidence strength: Preliminary; primarily animal and mechanistic data, with emerging clinical interest.

A 2023 study aimed to understand the effect of wheat-derived arabinoxylan on gut microbiota, colonic regulatory T cells (Tregs), and experimental colitis. Healthy and chronic colitis model mice were fed chow containing cellulose or wheat-derived arabinoxylan for 2–6 weeks. A 16S-based metagenomic analysis revealed that Lachnospiraceae, comprising butyrate-producing and Treg-inducing bacteria, were overrepresented in arabinoxylan-fed mice. In line with the changes in the gut microbiota, both the fecal butyrate concentration and the colonic Treg population were elevated in arabinoxylan-fed mice. In a T cell transfer model of chronic colitis, wheat-derived arabinoxylan ameliorated body weight loss and colonic tissue inflammation, which may in part be mediated by Treg induction. Moreover, wheat-derived arabinoxylan suppressed TNFα production from type 1 helper T cells in this colitis model. These findings are preclinical and require validation in human IBD populations.

6.3 Blood Glucose and Glycemic Control

Evidence strength: Moderate-to-good for postprandial glycemia; weaker for long-term chronic glycemic control markers in clinical populations.

A foundational randomized crossover trial in 15 subjects with Type II diabetes (Monash Medical Centre, Australia) found that diet supplementation with arabinoxylan-rich (AX) fibre from wheat was investigated for effects on glycaemic control in a randomised, crossover intervention trial at Monash Medical Centre. Subjects supplemented their usual diet with control bread and muffins or with AX-bread and muffins (50% whole wheat, 36% white flour, 14% AX fibre). The AX diet supplied an additional 15.1 g/day dietary fibre. Consumption of the AX diet increased faecal output by 61.5 g/day (wet weight basis, P=0.05) and significantly lowered fasting and 2-hour plasma glucose, 2-hour insulin, and serum fructosamine (P=0.002, 0.000, 0.015, and 0.02, respectively). Blood lipids, body weight, fat mass and blood pressure remained unchanged. A supplement of 15 g/day of AX-rich fibre can significantly improve glycaemic control in people with Type II diabetes.

In a randomized, single-blind, crossover study in 11 adults with impaired glucose tolerance (IGT), subjects consumed either white bread rolls as a placebo or supplemented with 15 g arabinoxylan for 6 weeks with a 6-week washout period. Fasting serum glucose, serum triglycerides, and apolipoprotein A-1 were significantly lower during arabinoxylan consumption compared to placebo (p=0.029, p=0.047; p=0.029, respectively). No effects of arabinoxylan were observed for insulin, adiponectin, leptin, and resistin, as well as apolipoprotein B and unesterified fatty acids. In conclusion, the consumption of AX in subjects with impaired glucose tolerance improved fasting serum glucose and triglycerides. However, this beneficial effect was not accompanied by changes in fasting adipokine concentrations.

In a related crossover trial in 7 female and 4 male adults with IGT (aged 55.5 years, BMI 30.1 kg/m²), subjects received either placebo or 15 g AX supplement for 6 weeks with a 6-week washout period in-between. Postprandial glucose, insulin, and ghrelin responses were measured in detail.

A major 2025 systematic review and meta-analysis (published in Nutrients) encompassing 133 studies — including 46 clinical and 25 preclinical trials — provided the most comprehensive synthesis to date. AX consumption improved overall postprandial glycemic control in clinical studies, as evidenced by reductions in glucose iAUC (SMD: −0.41; 95% CI: [−0.57, −0.25]), insulin iAUC (SMD: −0.28; 95% CI: [−0.44, −0.12]), glucose iPeak (SMD: −0.52; 95% CI: [−0.80, −0.25]), and insulin iPeak (SMD: −0.24; 95% CI: [−0.41, −0.06]) compared to the control. However, for chronic glycemic control, fasting glucose (Hedges' g: −1.18; 95% CI: [−1.56, −0.80]), insulin (Hedges' g: −1.07; 95% CI: [−1.92, −0.23]), HbA1c (Hedges' g: −2.93; 95% CI: [−5.48, −0.38]), and HOMA-IR (Hedges' g: −2.44; 95% CI: [−3.66, −1.22]) reduced in preclinical studies, while improvements were limited to fasting glucose (MD: −0.10; 95% CI: [−0.16, −0.03]) in clinical studies. This discrepancy between animal and human evidence for chronic outcomes warrants caution.

A 2024/2025 meta-analysis of 30 RCTs involving 1,140 participants found that intrinsic AXs effectively reduced fasting blood glucose (SMD: −0.44; 95% CI: −0.75, −0.13; p = 0.005; I² = 60%) and systolic blood pressure (MD: −2.86; 95% CI: −5.45, −0.27; p = 0.03; I² = 0%).

6.4 Lipid Profile and Cardiovascular Risk

Evidence strength: Preliminary to moderate; some positive signals for LDL reduction, but large definitive RCTs are lacking.

In studying the effect of two types of fiber supplements — inulin and arabinoxylan (found in grains) — Stanford researchers found substantial differences in their effects. For many participants, higher arabinoxylan was linked to fewer cardiovascular risk factors, particularly a drop in low-density lipoprotein (LDL) cholesterol. Researchers also saw a reduction in LDL levels during the mixed supplement cycle, but it was not as pronounced as the drop induced by just arabinoxylan, suggesting that purified supplements may be more effective at reducing cholesterol.

Exactly how fiber tamps down LDL has yet to be determined, but in this study, researchers caught a glimpse of how that may happen. The study showed that high fiber consumption led to a rise in gut-bacteria-derived bile acids, which break down cholesterol and other lipids, and that there was a decrease in certain lipids. The results suggest that the microbiome's response plays an important role in reducing LDL.

From the 5-week crossover trial in 15 people with Type II diabetes, blood lipids, body weight, fat mass, and blood pressure remained unchanged with AX supplementation, suggesting lipid effects may not be consistent across all populations or study designs.

An independent review assessment concluded that while there is scientific rationale and some preliminary human data supporting the use of arabinoxylan for cholesterol management, the evidence base is not robust, and large, well-designed clinical trials are lacking. Therefore, arabinoxylan may have a cholesterol-lowering effect, but it is less substantiated than other dietary fibers.

6.5 Immune Function (RBAC / Biobran / MGN-3)

Evidence strength: Preliminary to moderate; human trials exist but are mostly small, short-term, and focused on specific RBAC preparations. Independent replication is limited.

A comprehensive literature review explored biologically active compounds and mechanisms of action supporting RBAC as an immunomodulating nutraceutical in generally healthy and/or aging individuals. Thirty-seven primary research articles fulfilled the selection criteria for review.

RBAC can enhance both innate and adaptive immune systems in eliminating pathogens and malignant cells. The innate immunity is enhanced via up-regulating the cytotoxic activity of natural killer (NK) cells with increased granularity. RBAC's effects on NK cell activity were demonstrated in vivo in different mouse models, in vitro with different cell lines, and in human trials. RBAC can also enhance the phagocytic cellular functions of macrophages, neutrophils, and monocytes.

A key randomized, double-blind, placebo-controlled human trial enrolled 12 healthy geriatric subjects (over 56 years old). A total of six subjects served as control and six subjects ingested Biobran/MGN-3 (500 mg/day) for 30 days. The effect of Biobran/MGN-3 supplementation on NK/NKT cell activity was assessed using the degranulation assay. Results demonstrated that Biobran/MGN-3 had no effect on the total percentage of NK cells, however it enhanced the cytotoxic activity of induced NK cell expression of cluster of differentiation 107a (CD107a), when compared with baseline values and with the placebo group (P<0.05). Furthermore, there were no side effects observed, indicating that Biobran/MGN-3 supplementation was safe at the utilized dosage and for the duration of administration. Additional beneficial effects included improved mean corpuscular volume and reduced hepatic aspartate aminotransferase enzyme levels, which suggested improved liver function.

Mean NKC CD107a expression significantly increased (p = 0.004) from 49.5 ± 10.4% to 75.2 ± 6.6% for the Biobran MGN-3 group compared to an insignificant difference in pre- and post-treatment values in the placebo group (45.3 ± 12 vs. 50.8 ± 19.5). The enhanced NKC activity stimulated by RBAC could be sustained for 3 months in the geriatric group.

Human clinical trials with geriatric participants have demonstrated RBAC to have prophylactic benefits against viral infection and may improve their quality of life. However, further research should explore RBAC's bioavailability, pharmacodynamics, and pharmacokinetics of the complex heteropolysaccharides within. Translational research to assess RBAC as a nutraceutical for the aging population is still required, particularly in human studies with larger sample sizes and cohort studies with long follow-up periods.

6.6 Gastrointestinal Tolerance and Bowel Function

Evidence strength: Good for gastrointestinal tolerability at doses up to approximately 13 g/day.

A randomized, double-blind, placebo-controlled, crossover trial in 45 subjects (M/F: 29/16; aged 47.8 ± 9.6 years; BMI 27.9 ± 4.4 kg/m²) assessed AX wheat fiber extract. Subjects were randomly assigned to consume maltodextrin placebo or AX wheat fiber extracts providing 6.37 g AX/day (low-dose) or 12.74 g AX/day (high-dose) for 3 weeks. There were no statistically significant differences between placebo and either AX dose in the area under curve of the gastrointestinal tolerance questionnaire (GITQ) composite score, as well as severity rating of individual symptoms (P > 0.05). Stool frequency, stool consistency, straining during bowel movements, discomfort during bowel movements, and sensation of incomplete evacuation did not differ between interventions. There were no reported adverse events judged to be related to the AX wheat fiber extract product. Consumption of prebiotic AX wheat fiber extract providing 6.37 or 12.74 g AX per day for 3 weeks did not affect GI tolerance symptom severity or bowel habits and did not result in related adverse events, suggesting that the product is safe and well-tolerated.

7. Body Systems and Health Areas

• Gastrointestinal system: Prebiotic fermentation substrate; modulation of gut microbiota composition; promotion of beneficial bacteria (Bifidobacterium, Lactobacillus, Roseburia, Lachnospiraceae); SCFA production; support of intestinal barrier integrity; bulk-forming effect on stool.
• Metabolic / endocrine: Attenuation of postprandial glucose and insulin excursions; modest reduction in chronic fasting glucose in clinical studies; triglyceride reduction in IGT populations; potential effects on ghrelin (appetite hormone) secretion.
• Cardiovascular: Potential LDL cholesterol reduction, likely mediated by gut-bacteria-derived bile acid metabolism; systolic blood pressure reduction seen in intrinsic AX trials.
• Immune system: In the form of RBAC, upregulation of NK cell cytotoxic activity; enhancement of macrophage phagocytosis; augmentation of adaptive immunity through dendritic cell maturation and T and B lymphocyte proliferation; inhibition of mast cell degranulation.
• Antioxidant: Via esterified ferulic acid residues and their liberation during fermentation; activation of the Keap1-Nrf2 antioxidant signaling pathway.
• Inflammatory modulation: Reduction of NF-κB signaling via SCFA-mediated HDAC suppression; TNFα suppression in preclinical colitis models.

8. Dosage Forms and Doses Reported in Studies

The following dosages are drawn directly from published human studies; they do not represent prescriptive recommendations.

• Glycemic / metabolic trials (AX-enriched bread/muffins): The AX diet supplied an additional 15.1 g/day dietary fibre (mean, 95% CI: 12.0–18.5). A supplement of 15 g/day of AX-rich fibre can significantly improve glycaemic control in people with Type II diabetes.
• IGT crossover trial (wheat AX capsules/bread): Subjects received either placebo or 15 g AX supplement for 6 weeks with a 6-week washout period.
• AXOS in bread (prebiotic): Breads contained 2.2 g AXOS.
• AXOS prebiotic — healthy individuals: Consumption of 2.4 g AXOS per day for 3 weeks significantly increased bifidobacteria and short-chain fatty acid concentrations.
• AX wheat fiber extract (GI tolerability): 6.37 g AX/day (low-dose) or 12.74 g AX/day (high-dose) for 3 weeks.
• RBAC / Biobran (immune — geriatric trial): Six subjects ingested Biobran/MGN-3 at 500 mg/day for 30 days.
• RBAC gut microbiome study: Ten volunteers supplemented their diet with 1 g of RBAC for six weeks and 3 g of RBAC for another six weeks, with a three-week washout period.

9. Safety Considerations and Interactions

9.1 General Tolerability

Consumption of prebiotic AX wheat fiber extract product containing 6.37 or 12.74 g AX per day for 3 weeks did not affect GI tolerance symptom severity and bowel habits and stool consistency in adults and did not result in related adverse events, suggesting that the product is safe and well-tolerated.

When taken by mouth, arabinoxylan might cause diarrhea, gas, or stomach pain — consistent with the known fermentative activity of soluble fibers in the colon at higher doses or in unacclimated individuals.

9.2 Hepatic Safety (RBAC)

Rice Bran Arabinoxylan Compound (RBAC) results from an enzymatic modification of rice bran, which is reported to have immunomodulatory, anti-oxidant, and anti-inflammatory effects by regulating the production of pro-inflammatory cytokines. A systematic review and meta-analysis aimed to determine the hepatic adverse effects of RBAC by assessing the effect through liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The conclusion was that RBAC supplementation seems to not have any hepatic adverse effects, and its supplementation as powder or for three months and more may decrease serum AST levels. The authors noted that further studies are needed to confirm the results.

9.3 Immunosuppressant Interactions

Because RBAC upregulates immune cell activity, there is a theoretical concern — noted in pharmacological references — about its use alongside immunosuppressant drugs. Extra care is warranted in people who have had a transplant, are on chemotherapy, or have an autoimmune disease. RBAC should not be taken with drugs that decrease or suppress the immune system, including azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, prednisone, or dexamethasone. This caution is pharmacologically plausible given the demonstrated NK-cell and macrophage-stimulating activities of RBAC, but the interaction has not been empirically tested in controlled human trials.

9.4 Allergy Considerations

Extra care is advised for individuals who are allergic to mushrooms, yeast, or rice bran when using RBAC-based products, given their derivation from rice bran treated with Lentinus edodes (shiitake) mycelium. Persons with wheat allergy or celiac disease should also use caution with wheat-derived AX preparations.

9.5 Pregnancy and Lactation

Not enough is known about the use of arabinoxylan during pregnancy and breast-feeding to characterize its safety in these populations.

9.6 Evidence Gaps and Limitations

Most studies do not investigate the effect of AX as a pure ingredient on food systems, but as fibres containing AXs (such as bran). Therefore, AX's benefit for human health deserves further investigation. Clinical trials conducted to date are typically short in duration (5–12 weeks), involve small sample sizes, and use heterogeneous AX preparations from varying sources and with differing structural properties, making direct inter-study comparison difficult. The structural diversity of AX — varying by cereal source, molecular weight, degree of branching, and solubility — substantially affects its biological activity, and this complexity is not consistently controlled across studies.

References

• Deehan EC et al. "Arabinoxylans as Functional Food Ingredients: A Review." Nutrients. 2022; PMC8997659
• Maher T et al. "Changes in the Human Gut Microbiome during Dietary Supplementation with Modified Rice Bran Arabinoxylan Compound." PMC10385627. 2023.
• Cereal-Derived Water-Unextractable Arabinoxylans: Structure Feature, Effects on Baking Products and Human Health. PMC11311280. 2024.
• Chudan S et al. "Effect of Wheat-Derived Arabinoxylan on the Gut Microbiota Composition and Colonic Regulatory T Cells." Molecules. 2023; PMC10096111.
• Damen B et al. "A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers." PMC3487838. 2012.
• Lee MC et al. "In Vitro Fecal Fermentation Patterns of Arabinoxylan from Rice Bran on Fecal Microbiota from Normal-Weight and Overweight/Obese Subjects." PMC8232586. 2021.
• Xu Y, Liang Y, Kim JE. "Impact of Arabinoxylan Consumption on Glycemic Control: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies." Nutrients. 2025; PMC12429902.
• Garcia AL et al. "Arabinoxylan fibre consumption improved glucose metabolism, but did not affect serum adipokines in subjects with impaired glucose tolerance." Horm Metab Res. 2006. PubMed 17111305.
• Lu ZX et al. "Arabinoxylan fibre improves metabolic control in people with Type II diabetes." Eur J Clin Nutr. 2004. PubMed 15042130.
• Garcia AL et al. "Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance." Eur J Clin Nutr. 2007.
• Shareh A et al. "Modified Rice Bran Arabinoxylan by Lentinus edodes Mycelial Enzyme as an Immunoceutical for Health and Aging — A Comprehensive Literature Review." PubMed 37687141. 2023.
• Modified Rice Bran Arabinoxylan by Lentinus edodes Mycelial Enzyme as an Immunoceutical for Health and Aging — A Comprehensive Literature Review. PMC10488663. 2023.
• Barir M et al. "The Health-Promoting Properties and Clinical Applications of Rice Bran Arabinoxylan Modified with Shiitake Mushroom Enzyme — A Narrative Review." PMC8123671. 2021.
• Ghoneum M, Agrawal S. "Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial." PubMed 29456638. 2018.
• Baxter NT et al. "The Effect of Arabinoxylan on Gastrointestinal Tolerance in Generally Healthy Adults: A Randomized, Placebo-Controlled, Crossover Study." PMC8180805. 2021.
• Noormohammadi M et al. "Is there any hepatic impact associated with rice bran arabinoxylan compound supplementation? A systematic review and dose-response meta-analysis of randomized controlled trials." Clin Nutr ESPEN. 2023. PubMed 37739721.
• Xu Y et al. "Ferulic acid mediates prebiotic responses of cereal-derived arabinoxylans on host health." Front Nutr. 2022; PMC9344318.
• Mendez-Encinas MA et al. "Ferulated Arabinoxylans and Their Gels: Functional Properties and Potential Application as Antioxidant and Anticancer Agent." Oxid Med Cell Longev. 2018; PMC6116397.
• Palencia R et al. "Arabinoxylan-Based Particles: In Vitro Antioxidant Capacity and Cytotoxicity on a Human Colon Cell Line." PMC6681090. 2019.
• Deehan EC et al. "Gut microbiota modulation with long-chain corn bran arabinoxylan in adults with overweight and obesity is linked to an individualized temporal increase in fecal propionate." Cell Host Microbe. 2020; PMC7439537.
• Isolation and identification of feruloylated arabinoxylan mono- and oligosaccharides from undigested and digested maize and wheat. PMC4946213.
• Neyrinck AM et al. "Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice." PMC3302144. 2012.
• Barber H et al. "Cereal Grain Arabinoxylans: Processing Effects and Structural Changes during Food and Beverage Fermentations." Fermentation. 2023.
• Arabinoxylans. Encyclopedia MDPI. 2022.
• Arabinoxylan — An Overview. ScienceDirect Topics.
• FDA Scientific Evaluation for Declaring Dietary Fiber on Nutrition and Supplement Facts Labels. Current Developments in Nutrition. 2024.
• Stanford Medicine News: "Fiber supplements aren't one-size-fits-all, study shows." 2022.
• Qaisrani TB et al. "Arabinoxylans from psyllium husk: A review." J Environ Agric Sci. 2016.
• Evaluating the effects of intrinsic and isolated arabinoxylans on human gut microbiota and short-chain fatty acids: A systematic review and meta-analysis. Food Research International. 2024.
• Adaptation to tolerate high doses of arabinoxylan is associated with fecal levels of Bifidobacterium longum. PMC11174067. 2024.